Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 12/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3623417 | 0.85 | PDK2 (0.42) | L3MBTL1PDK2MAPK1ALDH1A1 | |
| SCHEMBL4974371 | 0.78 | KCNA5 (0.50) | L3MBTL1PDK2ALDH1A1MKNK1MKNK2 | |
| SCHEMBL4975470 | 0.77 | KCNA5 (0.51) | L3MBTL1ALDH1A1 | |
| SCHEMBL2063286 | 0.76 | KCNA5 (0.64) | L3MBTL1CREBBPPDK2MAPK1 | |
| SCHEMBL1368851 | 0.75 | L3MBTL1 (0.55) | L3MBTL1CREBBPPDK2MAPK1ALDH1A1 | |
| SCHEMBL5043791 | 0.74 | L3MBTL1 (0.50) | L3MBTL1CREBBPPDK2MAPK1ALDH1A1 | |
| SCHEMBL4979371 | 0.73 | HTR2A (0.44) | MAPK1 | |
| SCHEMBL4980305 | 0.70 | KCNA5 (0.39) | MAPK1 | |
| SCHEMBL4784136 | 0.70 | L3MBTL1 (0.60) | L3MBTL1CREBBPPDK2MAPK1ADORA2A | |
| SCHEMBL10094644 | 0.68 | CREBBP (0.69) | L3MBTL1CREBBPPDK2ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067607-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100004229-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004229-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | L3MBTL1 1720/4885CREBBP 4399/4885PDK2 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.